{"entity":{"id":"paper-mesothelin-mesothelioma-clin-cancer-res-2004","kind":"paper","name":"Mesothelin: a new target for immunotherapy","aka":[],"tldr":"Review on Mesothelin in Mesothelioma, in Clinical Cancer Research (2004), one of the most cited Europe PMC records with Mesothelin in its title.","summary":"Mesothelin is a differentiation antigen present on normal mesothelial cells and overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinoma. The mesothelin gene encodes a precursor protein that is processed to yield the 40-kDa protein, mesothelin, attached to the cell membrane by a glycosylphosphatidyl inositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor. The biological function of mesothelin is not known. Mesothelin is a promising candidate for tumor-specific therapy, given its limited expression in normal tissues and high expression in several cancers. SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin that is undergoing clinical evaluation in patients with mesothelin-expressing tumors. There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas.\n\nIndexed on Europe PMC as PubMed record 15217923 (DOI 10.1158/1078-0432.ccr-03-0801). Its title names Mesothelin and its text names Mesothelioma; PubMed types it as a review (Research Support, Non-U.S. Gov't, Review). It was matched automatically to the idea \"Treat the body cavity, not the bloodstream, for surface spread\" and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Clin Cancer Res 2004","url":"https://doi.org/10.1158/1078-0432.ccr-03-0801"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/15217923/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/15217923"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2004,"doi":"10.1158/1078-0432.ccr-03-0801","pmid":"15217923","authors":"Hassan R, Bera T, Pastan I","paperType":"review","findings":[],"whatItMeans":"One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched by Mesothelin in the title and Mesothelioma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","A review summarises other studies; the primary reports it cites are the evidence."]},"route":"/key-papers/paper-mesothelin-mesothelioma-clin-cancer-res-2004/","neighbours":{"journal":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/"}],"idea":[{"id":"idea-adc-for-mesothelioma","kind":"idea","name":"Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work","route":"/ideas/idea-adc-for-mesothelioma/"},{"id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/"},{"id":"idea-bio2-intracavitary-immunotherapy","kind":"idea","name":"Treat the body cavity, not the bloodstream, for surface spread","route":"/ideas/idea-bio2-intracavitary-immunotherapy/"}]}}